Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2014 Sep 1.

Published in final edited form as: HIV Clin Trials. 2013 Sep-Oct;14(5):224–234. doi: 10.1310/hct1405-224

Mean total bone mineral density (TBMD) percentage change from baseline over time according to antiretroviral (ARV) regimen. (A) Modified intent-to-treat (ITT) population. (B) As-treated (AS) population. (C) Model-based estimated TBMD changes (modified ITT population). d4T = stavudine; EFV = efavirenz; LPV = lopinavir/ ritonavir; TDF = tenofovir; Sparing = efavirenz plus lopinavir/ ritonavir; ZDV = zidovudine.

Note: Changes for ZDV and d4T plots were intentionally offset for display purposes. There was no difference between ZDV and d4T found in the model.

Mean total bone mineral density (TBMD) percentage change from baseline over time according to antiretroviral (ARV) regimen. (A) Modified intent-to-treat (ITT) population. (B) As-treated (AS) population. (C) Model-based estimated TBMD changes (modified ITT population). d4T = stavudine; EFV = efavirenz; LPV = lopinavir/ ritonavir; TDF = tenofovir; Sparing = efavirenz plus lopinavir/ ritonavir; ZDV = zidovudine.

Note: Changes for ZDV and d4T plots were intentionally offset for display purposes. There was no difference between ZDV and d4T found in the model.